A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Table 2 Comparative prognostic performance of nine different breast cancer gene signatures in the HRneg validation cohort (n = 75)

Breast cancer gene signatures	Univariate Cox regression		Kaplan-Meier analysis
	Hazard ratio (95% confidence interval)	Pvalue	Log-rank Pvalue
HRneg/Tneg	2.38 (1.02-5.58)	0.045	0.039
STAT1 cluster [23]	2.06 (0.88-4.82)	0.095	0.088
IR-7 [25, 26]	2.17 (0.93-5.07)	0.075	0.068
IFN cluster [24]	1.62 (0.71-3.71)	0.25	0.25
ONCO-RS [19]	1.45 (0.64-3.27)	0.37	0.36
GGI [21, 31]	0.68 (0.30-1.53)	0.35	0.35
MS-14 [16]	0.84 (0.38-1.88)	0.68	0.68
NKI-70 [6]	1.33 (0.59-2.97)	0.49	0.49
CSR/wound [18]	0.68 (0.30-1.54)	0.36	0.35

CSR, core serum response; GGI, genomic grade index; HRneg, hormone receptor-negative; IFN, interferon; IR-7, immune response signature with 7-gene immune response module; MS-14, Celera 14-gene metastasis score; NKI-70, 70-gene Mammaprint signature; ONCO-RS, Oncotype/Genomic Health recurrence score; STAT1, signal transducer and activator of transcription 1; Tneg, triple-negative.

ISSN: 1465-542X